Emergent BioSolutions Inc 2025年度报告

AnnualReport29 Preparednesstoday,safertomorrow Dear Fellow Shareholders, In2025,wemademeaningfulprogresstowardourmulti-yearstrategytoturnaroundandtransform Emergent.Aswe continue ourtransformation journey,we remain committedto ourmission to protect and save lives, while prioritizing patient safety, quality and complianceandadvancing the operational and strategic priorities essential to long-termgrowth focused,lean and efficientbusinessmodel,strongoperating results,margin improvementsoperational initiatives executed in 2024, enhanced our balance sheet and reinforced thefoundation needed to support sustainable value creation. We successfully achieved several important milestones, including: ·Delivered strong earnings and cash flow,improved ourcash balanceby$100M andreduced our debt by $110M..SecuredmultipleU.S.governmentcontractawardsforbiodefensepreparednessanddelivered medical countermeasures to over 20 countries.Distributedover100million doses ofNARCAN?Nasal Sprayacross theU.S.andCanadasince2016., Expanded naloxone portfolio by acquiring exclusive commercial rights to KLOxXADO?(naloxone HCI) Nasal Spray8 mg and maintained market leadership position forNARCANNasal Spray 4mg.·Divested Baltimore-Bayview facility for $36.5M while retainingrights to securemanufacturing capacityfor future growth..Received U.S.FDA approval for drug product manufacturing of raxibacumab atWinnipeg facility.·Announced investment agreement with Swiss Rockets AG and pursued strategiccollaboration with its subsidiary Rocketvax..Advanced key initiatives to enhance quality and operational excellence across theenterprise. Lookingahead,wearefocusedonthetransformationofourcompanyby investingin revenuegrowthdrivers across both the MCMandnaloxonebusinessesbyadvancing our internalpipeline,expanding ourinternationalrevenueand pursuingtargetedacquisitionsandexternal opportunities that leverage our infrastructure and scale. Ourproductshelpprotectcommunitiesandaddresscriticalpublichealthchallengeslikesmallpox,anthrax,botulism,Ebola andopioid overdoses.Iwantto expressmydeepestgratitude to my incredible colleagues at Emergent for another strong year of achievementsand advancements.WebelieveEmergentis wellpositionedto delivera strong 2026andbeyond. We are confident in our ability to transform the company and fulfll our missiontoprotectandsavelives. Joe PapaPresident and CEO UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM10-K Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405of Securities Act.YesNo Indicate bycheck mark if theregistrant is notrequired tofile reports pursuant to Section 13 or Section 15(d)ofthe Act.YesNo Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Actof1934 during the preceding 12 months (orfor such shorterperiod that theregistrant was required tofile such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant Rule 405 of Regulation S-T (s 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit such files).Yes μ No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "non-acceleratedfiler","smaller reporting company" and“emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filerAccelerated filer Non-accelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicatebycheckmarkwhethertheregistrant has filed a reporton and attestationto its management's assessmentofthe effectivenessaccounting firm that prepared or issued its audit report. Yes No If securitiesare registered pursuanttoSection12(b)of the Act,indicate bycheck mark whetherthe financial statementsof theregistrantincluded in thefiling reflectthecorrectionof an errorto previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant's executive officers during the relevant recovery period pursuant to s240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No The aggregate market value of voting and non-voting common equity held by non-affiliates of the regis